Acyclovir versus placebo for HSV-2 meningitis
Treatments studied
Part of Brain & nervous system, Infections clinical trials.
This study compares acyclovir (an antiviral medicine) to placebo (inactive treatment) in adults with HSV-2 meningitis. It aims to see whether acyclovir helps people recover faster or better after this infection of the lining around the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- Doctors suspect viral meningitis based on symptoms, and it is confirmed by a spinal fluid test
- Your spinal fluid (CSF) shows high white blood cells and tests positive for HSV-2 by PCR
- You are fully alert (Glasgow Coma Scale score of 15)
- You can take and absorb pills by mouth
- You do not have certain related conditions or major health exclusions (like pregnancy or severe kidney/liver problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether acyclovir, an antiviral drug, can help patients with pneumonia who are on breathing support and have herpes simplex virus in their lung fluid. The goal is to see if it improves recovery.
This study tests whether giving acyclovir early—before symptoms appear—can help patients on a breathing machine who have a herpes virus in their throat. It aims to see if treatment can prevent complications and improve recovery.
This trial tests whether a medicine called acyclovir can prevent herpes simplex outbreaks in people who also have an autoimmune rheumatic disease. It may help reduce the number of painful cold sores or genital herpes episodes you experience.
This study looks at the best way to treat meningitis in adults right away and then checks how people recover over time. It aims to improve care and recovery for patients.
This study tests a new mRNA vaccine designed to protect against herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes. It is for healthy adults who have not had a genital herpes outbreak in the last 6 months.
This study checks how acyclovir behaves in the body when it’s given by mouth or through an IV to children receiving cancer care. It may help doctors better choose doses and monitor the medicine in kids who need prevention or treatment of certain viral infections.
Hear when a new Herpes Simplex 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.